Centessa Pharma rises on FDA nod to begin human trials for tumor therapy

Centessa Pharmaceuticals

26/01/2023 19:03

** U.S.-listed shares of UK-based drug developer Centessa
Pharmaceuticals PLC  CNTA.O  rise 1.8% to $3.91 
    ** Co says the U.S. Food and Drug Administration (FDA) has
cleared the application to begin human trials for its
antibody-based drug being developed for solid tumors 
    ** The drug candidate, LB101, targets proteins such as CD47
and PD-L1 that are overexpressed in tumor cells - CNTA  
    ** Including session moves, stock has fallen ~58.3% in the
past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))